| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. | Mol Cancer Ther | 2010 | 1.70 |
| 2 | Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. | PLoS One | 2012 | 1.22 |
| 3 | Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. | Free Radic Biol Med | 2010 | 0.94 |
| 4 | Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. | Eur J Pharm Sci | 2012 | 0.86 |
| 5 | Histone modifications: implications in renal cell carcinoma. | Epigenomics | 2013 | 0.80 |
| 6 | Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer. | Future Oncol | 2015 | 0.75 |